JOURNAL OF THE AMERICAN COLLEGE OF ANGIOLOGY

The Official Journal of the American College of Angiology

May/June 2003	Volume 1	Number 1
CONTENTS		
Original Articles		
A Systematic Review of Nebive Ton J. Cleophas, MD, Ph.D., Ouwerkerk, MD	olol, a Novel Third Generation Selective Beta-blocker FACA; Jan van der Meulen, MD; and Bas van	101
Time Sequence of Endotoxemi E. Bölke, MD, FACA; A. Sch	a and Mediator Response in Abdominal and Cardiac Surphwarz; G. Steinbach; and K. Orth, MD, Ph.D.	gery 113
Myocardial Infarction Complic	wrooz S. Joolhar, MD; Joseph I. Lee, MD; John P.	121
Angina and Coronary Ischemic R.M. Fleming, MD, FACA	a Are the Result of Coronary Regional Blood Flow Differe	ences 127
After Myocardial Infarction	Protein Associates with Pronounced Autonomic Imbalance Mar Kaasik; and Rein Teesalu	143
Post-thrombotic Syndrome after R. Eisele, MD; F. Langhoff, I	er Calf Vein Thrombosis, A 10-Year Follow-Up MD; and L. Kinzl, Ph.D.	147
Isolated Systolic Hypertension Ton J. Cleophas, MD, Ph.D., Ouwerkerk, MD	and Nitrates, A Review FACA; Jan van der Meulen, MD; and Bas van	159
Using C-Reactive Protein as a l Acute Coronary Syndromes Richard M. Fleming, MD, FA	Marker of Bacterially Aggravated Atherosclerosis in	165

The information presented in the papers and the opinions expressed therein are those of the individual author(s) and do not necessarily reflect the views of the American College of Angiology, Inc. The Publisher assumes no liability for any material published in the Journal. All statements are the responsibility of the author(s).

The Journal of the American College of Angiology is published 6 times per year by the American College of Angiology, Inc. Editorial and Business Office, 293 Northern Blvd., Ste. 104, Great Neck, NY 11021, U.S.A. Copyright @2003 by the American College of Angiology, Inc. All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means electronic, mechanical, photocopying, recording, or otherwise without the prior written permission of the College.

Using C-Reactive Protein as a Marker of Bacterially Aggravated Atherosclerosis in Acute Coronary Syndromes

Richard M. Fleming, MD, FACA

Background—Inflammatory and infectious markers such as C-reactive protein (CRP) have been proposed as indicators of the development or progression of coronary artery disease resulting from bacterial invasion of atherosclerotic plaques. The incidence of such bacterial involvement and its treatment response has not been clearly elucidated in the clinical setting. This study prospectively looked at individuals with newly diagnosed coronary artery disease (CAD), the incidence of elevated CRP levels, the association with acute phase antibodies (APA), detectability of the thymus gland, and macrolide antibiotic treatment response in individuals with bacterially aggravated atherosclerosis (BAA).

Methods—In part 1 of this study, 132 patients (44 women and 88 men), were studied via myocardial perfusion imaging (MPI) using high-dose dipyridamole (HDD) and Sestamibi injection following standardized single photon emission computed tomography (SPECT) and anterior (thymus) planar imaging. All 132 had blood drawn to measure CRP concentrations. When CRP levels were elevated, APAs for H. pylori, C. pneumoniae, and S. pneumoniae were measured. Results of CRP, APAs, and MPI and thymus imaging (TI) were compared. Thymus imaging was repeated following MPI. In part 2, individuals with elevated CRP and APA were treated for 2 weeks with macrolide antibiotic therapy and then restudied 2 weeks following completion of successful antibiotic therapy.

Results—In part 1, of this study, 34 of the 132 patients with newly diagnosed CAD had elevated CRP levels. Of these, 32 (94%) of the 34 had APA for H. pylori and/or C. pneumoniae. No patients had APA for S. pneumoniae. The remaining 2 individuals with elevated CRP levels had ulcerative colitis. Thymus gland activity was present during the anterior planar imaging period in 100% (34 of 34) of those with elevated CRP levels. Efforts to measure thymus activity 40 minutes later, following MPI, were unsuccessful. In part 2, 32 of the original 132 patients (24%) with elevated CRP and APA levels were restudied 2 weeks after completion of their 2 weeks of macrolide antibiotic therapy. In 100% of them (11 women and 21 men), the CRP normalized, and APAs were no longer elevated. Improvement in CAD was also seen on MPI.

Conclusion—Bacterially aggravated atherosclerosis (BAA) was present in 24% (32 of 132) of patients with newly diagnosed CAD. In each, APAs for H. pylori and/or C. pneumoniae were detected in addition to thymus activity on planar imaging acquired immediately before MPI. In each instance, treatment with 2 weeks of macrolide antibiotic therapy resulted in normalization of CRP levels, absence of elevated APAs, and failure to detect thymus activity on follow-up imaging. Concomitant MPI demonstrated improvement in coronary blood flow following macrolide therapy, although to varying degrees for each individual, consistent with varying significance. Not all patients with elevated CRP levels had BAA, and care must be taken to distinguish which ones do, to avoid the indiscriminate use of antibiotics. When patients have BAA, macrolide treatment provides an additional treatment for CAD.

Key Words: • C-RP • Acute Coronary Syndromes • Bacterially aggravated atherosclerosis(BAA)

From The Camelot Foundation, Omaha and the Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska.

Journal of the American College of Angiology may be contacted at http://www.collegeofangiology.org